The TH1902 Docetaxel Peptide-Drug Conjugate Inhibits Xenografts Growth of Human SORT1-Positive Ovarian and Triple-Negative Breast Cancer Stem-like Cells

Background: Breast and ovarian cancer stem cells (CSC) can contribute to the invasive and chemoresistance phenotype of tumors. TH1902, a newly developed sortilin (SORT1)-targeted peptide-docetaxel conjugate is currently in phase-1 clinical trial. Whether TH1902 impacts the chemoresistance phenotype...

Descripción completa

Detalles Bibliográficos
Autores principales: Demeule, Michel, Charfi, Cyndia, Currie, Jean-Christophe, Zgheib, Alain, Danalache, Bogdan Alexandru, Béliveau, Richard, Marsolais, Christian, Annabi, Borhane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9503230/
https://www.ncbi.nlm.nih.gov/pubmed/36145658
http://dx.doi.org/10.3390/pharmaceutics14091910

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9503230/
https://www.ncbi.nlm.nih.gov/pubmed/36145658
http://dx.doi.org/10.3390/pharmaceutics14091910

Ejemplares similares